Combined hormone therapy and radiation therapy for locally advanced prostate cancer

被引：4

作者：

Bolla, M. ^{[1
,2
]}

Laramas, M. ^{[1
,2
]}

机构：

[1] CHU Michallon, Dept Radiat Oncol, F-38043 Grenoble 9, France

[2] Assoc Radiotherapy & Oncol Mediterranean ArEa, Paris, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2012年 / 84卷

关键词：

Locally advanced prostate cancer; Hormonal treatment; External irradiation;

D O I：

10.1016/j.critrevonc.2010.11.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The combination of radiotherapy and androgen suppression with luteinizing hormone releasing hormone agonist has become a standard of care for locally advanced prostate cancer. Phase III randomized trials have shown that for locally advanced prostate cancer a 4-month complete androgen blockade initiated 2 months prior radiotherapy and stopped at the completion of radiotherapy increased overall survival in patients with Gleason score 2-6, meanwhile an adjuvant long term androgen suppression (2.5-3 years) improved significantly overall survival. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：E30 / E34

页数：5

共 31 条

[1]

Bagshaw M A, 1988, NCI Monogr, P47

[2]

Bolla M, 2007, J CLIN ONCOL, V25

[3] Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].

Bolla, M ;

Collette, L ;

Blank, L ;

Warde, P ;

Dubois, JB ;

Mirimanoff, RO ;

Storme, G ;

Bernier, J ;

Kuten, A ;

Sternberg, C ;

Mattelaer, J ;

Torecilla, JL ;

Pfeffer, JR ;

Cutajar, CL ;

Zurlo, A ;

Pierart, M .

LANCET, 2002, 360 (9327) :103-108

[4] Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial [J].

Bolla, Michel ;

Hannoun-Levi, Jean Michel ;

Ferrero, Jean-Marc ;

Maingon, Philippe ;

Buffet-Miny, Joelle ;

Bougnoux, Agnes ;

Bauer, Jacques ;

Descotes, Jean-Luc ;

Fourneret, Philippe ;

Jover, Florence ;

Colonna, Marc .

RADIOTHERAPY AND ONCOLOGY, 2010, 97 (02) :312-317

[5] Duration of Androgen Suppression in the Treatment of Prostate Cancer [J].

Bolla, Michel ;

de Reijke, Theodorus M. ;

Van Tienhoven, Geertjan ;

Van den Bergh, Alphonsus C. M. ;

Oddens, Jorg ;

Poortmans, Philip M. P. ;

Gez, Eliahu ;

Kil, Paul ;

Akdas, Atif ;

Soete, Guy ;

Kariakine, Oleg ;

Van der Steen-Banasik, Elsbietha M. ;

Musat, Elena ;

Pierart, Marianne ;

Mauer, Murielle E. ;

Collette, Laurence .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) :2516-2527

[6] Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial [J].

Denham, JW ;

Steigler, A ;

Lamb, DS ;

Joseph, D ;

Mameghan, H ;

Turner, S ;

Matthews, J ;

Franklin, I ;

Atkinson, C ;

North, J ;

Poulsen, M ;

Christie, D ;

Spry, NA ;

Tai, KH ;

Wynne, C ;

Duchesne, G ;

Kovacev, O ;

D'Este, C .

LANCET ONCOLOGY, 2005, 6 (11) :841-850

[7]

HANKS GE, 1995, CANCER, V75, P1972, DOI 10.1002/1097-0142(19950401)75:7+<1972::AID-CNCR2820751636>3.0.CO

[8]

2-P

[9] Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 [J].

Hanks, GE ;

Pajak, TF ;

Porter, A ;

Grignon, D ;

Brereton, H ;

Venkatesan, V ;

Horwitz, EM ;

Lawton, C ;

Rosenthal, SA ;

Sandler, HM ;

Shipley, WU .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3972-3978

[10]

Heidenreich A, 2008, EUR UROL, V53, P68, DOI 10.1016/j.eururo.2007.09.002

← 1 2 3 4 →